8-K: Longeveron Announces Full-Year 2024 Financial Results and Provides Business Update

Longeveron reports a 237% increase in total revenue for 2024, driven by contract manufacturing and increased demand for the Bahamas Registry Trial, while advancing its Lomecel-BTM clinical programs.

Summary

• Longeveron Inc. reported its full-year 2024 financial results and provided a business update on February 28, 2025.
• Total revenue for 2024 increased by 237% year-over-year to $2.4 million, primarily due to contract manufacturing services and increased participant demand for the Bahamas Registry Trial.
• The company's pivotal Phase 2b clinical trial (ELPIS II) evaluating Lomecel-BTM in Hypoplastic Left Heart Syndrome (HLHS) has achieved over 90% enrollment and is expected to complete enrollment in the second quarter of 2025.
• Longeveron anticipates submitting a Biological License Application (BLA) for Lomecel-BTM for full traditional approval in 2026, contingent on the success of the ELPIS II trial.
• The company expects to meet with the FDA late in the first quarter of 2025 to discuss potential development paths for Lomecel-BTM in mild Alzheimer's disease.
• The WHO International Nonproprietary Names (INN) Expert Committee approved 'laromestrocel' as the non-proprietary name for Lomecel-B.
• The net loss for 2024 decreased to approximately $16.0 million, compared to a net loss of $21.4 million in 2023.
• As of December 31, 2024, cash and cash equivalents were $19.2 million, expected to fund operations into the fourth quarter of 2025.
• The company plans to seek additional financing to support BLA enabling activities and increased capital investments.

Sentiment

Score: 7

Explanation: The sentiment is moderately positive due to the significant revenue growth and reduced net loss. However, the need for additional financing and the dependence on clinical trial outcomes introduce uncertainty.

Positives

• Total revenue increased significantly by 237% to $2.4 million, driven by contract manufacturing and the Bahamas Registry Trial.
• Gross profit increased by 752% to $1.9 million.
• Net loss decreased by 25% to $16.0 million.
• General and administrative expenses decreased by 16% to $10.3 million.
• Research and development expenses decreased by 10% to $8.1 million.
• The ELPIS II trial for HLHS is progressing well with over 90% enrollment.
• Lomecel-BTM has received multiple FDA designations for HLHS and Alzheimer's disease.

Negatives

• The company is still operating at a net loss of $16.0 million for the year ended December 31, 2024.
• The company anticipates needing additional financing to support BLA enabling activities and increased capital investments.

Risks

• The company's future success is dependent on the outcome of clinical trials, particularly the ELPIS II trial for HLHS.
• The company needs to secure additional financing to fund its operations and BLA enabling activities.
• The company's cash and cash equivalents are expected to fund operations only into the fourth quarter of 2025.
• The company operates in a highly competitive and rapidly changing environment.

Future Outlook

Longeveron anticipates multiple potentially transformational milestones over the next 12 months, including completion of enrollment in the pivotal Phase 2b clinical trial in HLHS and a potential BLA submission for full traditional approval for HLHS. The company also plans to meet with the FDA to determine the development pathway for the Alzheimer's disease program. The company expects operating expenses and capital expenditure requirements to accelerate in calendar year 2025 and intends to seek additional financing and non-dilutive funding options to support these activities.

Management Comments

• Throughout 2024, we continued to advance the development of our investigational cellular therapy candidate, Lomecel-BTM, as a potential treatment for both Hypoplastic Left Heart Syndrome, or HLHS, and mild Alzheimers disease, said Wael Hashad, Chief Executive Officer of Longeveron.
• We are now approaching multiple potentially transformational milestones over the next 12 months, including, completion of enrollment in our pivotal Phase 2b clinical trial in HLHS, which may establish the timeline for a potential Biological License Application, or BLA, submission for full traditional approval for HLHS, and our upcoming meeting with the FDA to determine the development pathway for the Alzheimers disease program.
• Our teams expertise in clinical development and manufacturing, combined with several positive initial results across five clinical trials in three indications, continues to position Longeveron as a leader in stem cell therapy research and, potentially, commercialization of cellular therapeutics.

Industry Context

Longeveron is operating in the regenerative medicine and biotechnology industry, focusing on cellular therapies. The company's focus on HLHS and Alzheimer's disease aligns with the growing need for innovative treatments for these conditions. The FDA designations received by Lomecel-BTM highlight its potential in addressing unmet medical needs.

Comparison to Industry Standards

• Longeveron's 237% revenue increase is significant compared to other clinical-stage biotech companies, many of which rely solely on investment and partnerships before product approval.
• The company's focus on allogeneic MSC therapy aligns with a growing trend in regenerative medicine, with companies like Mesoblast also pursuing similar approaches.
• The 80% transplant-free survival rate at five years in the historical control data for HLHS provides a benchmark for Longeveron's Lomecel-BTM to improve upon, with the Phase 1 ELPIS I study showing 100% transplant-free survival.

Stakeholder Impact

• Shareholders: The increased revenue and reduced net loss are positive signs, but the need for additional financing could dilute shareholder value.
• Patients: Successful clinical trials could lead to new treatment options for HLHS and Alzheimer's disease.
• Employees: The company's growth and development programs could create new job opportunities.
• Investors: The company's progress and potential BLA submission could attract further investment.

Next Steps

• Complete enrollment in the ELPIS II clinical trial in Q2 2025.
• Meet with the FDA late in Q1 2025 to discuss development paths for Lomecel-BTM in mild Alzheimer's disease.
• Seek additional financing to support BLA enabling activities and increased capital investments.
• Potentially submit a BLA for Lomecel-BTM for full traditional approval in HLHS in 2026, if ELPIS II is successful.

Key Dates